Marshall Wace LLP Increases Stake in Arvinas, Inc. (NASDAQ:ARVN)

Marshall Wace LLP increased its stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 57.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 268,026 shares of the company's stock after buying an additional 97,676 shares during the quarter. Marshall Wace LLP owned approximately 0.39% of Arvinas worth $5,138,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of ARVN. Invesco Ltd. raised its stake in Arvinas by 1.6% in the fourth quarter. Invesco Ltd. now owns 37,254 shares of the company's stock valued at $714,000 after buying an additional 581 shares during the period. Rhumbline Advisers lifted its holdings in Arvinas by 0.9% during the 4th quarter. Rhumbline Advisers now owns 87,877 shares of the company's stock worth $1,685,000 after purchasing an additional 754 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Arvinas by 0.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 140,518 shares of the company's stock worth $2,694,000 after purchasing an additional 777 shares in the last quarter. Bank of Montreal Can boosted its stake in shares of Arvinas by 2.7% in the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock valued at $755,000 after buying an additional 1,044 shares during the period. Finally, KBC Group NV lifted its position in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after acquiring an additional 1,255 shares during the period. 95.19% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the sale, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,230 shares of company stock worth $769,402. Corporate insiders own 5.23% of the company's stock.

Arvinas Stock Up 3.4 %

ARVN traded up $0.31 during trading on Tuesday, reaching $9.52. 910,783 shares of the company were exchanged, compared to its average volume of 1,145,781. The company has a market cap of $654.85 million, a price-to-earnings ratio of -3.44 and a beta of 2.30. Arvinas, Inc. has a 12-month low of $5.94 and a 12-month high of $37.38. The company's 50-day moving average is $10.39 and its two-hundred day moving average is $17.88.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the firm earned ($2.53) EPS. Equities analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ARVN shares. BMO Capital Markets set a $20.00 target price on shares of Arvinas and gave the company an "outperform" rating in a research report on Wednesday, March 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. The Goldman Sachs Group reduced their target price on Arvinas from $15.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Truist Financial lowered their price target on Arvinas from $65.00 to $21.00 and set a "buy" rating for the company in a report on Wednesday, April 9th. Finally, Stifel Nicolaus decreased their target price on Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $34.33.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.